This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Excision repair cross-complementing factor 1 (ERCC1) analysis for non-small cell lung cancer (NSCLC) is considered experimental/investigational and therefore, non-covered. There is insufficient clinical evidence to support the routine use of this test in the care of NSCLC patients.
Excision Repair Cross-Complementing Factor 1 (ERCC1) Analysis for Non-Small Cell Lung Cancer is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting.
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.